{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T19:42:44Z","timestamp":1768678964658,"version":"3.49.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.mcna.2024.03.002","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T07:30:49Z","timestamp":1717572649000},"page":"923-951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Newer Outpatient Diabetes Therapies and Technologies"],"prefix":"10.1016","volume":"108","author":[{"given":"Nevin","family":"Kamal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grazia","family":"Aleppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.mcna.2024.03.002_bib2","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"9","key":"10.1016\/j.mcna.2024.03.002_bib3","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1111\/dom.13361","article-title":"Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"20","author":"Andreadis","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.mcna.2024.03.002_bib4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): A 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.002_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.mcna.2024.03.002_bib6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes Metab"},{"issue":"10","key":"10.1016\/j.mcna.2024.03.002_bib7","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.002_bib8","doi-asserted-by":"crossref","first-page":"e13435","DOI":"10.1111\/obr.13435","article-title":"Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials","volume":"23","author":"Iqbal","year":"2022","journal-title":"Obes Rev"},{"key":"10.1016\/j.mcna.2024.03.002_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: an updated review of head-to-head clinical studies","volume":"12","author":"Trujillo","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.mcna.2024.03.002_bib10","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.3390\/ijms23084334","article-title":"The role of Glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome","volume":"23","author":"Bednarz","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.002_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-18-0175","article-title":"Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study","volume":"179","author":"Salamun","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"10019","key":"10.1016\/j.mcna.2024.03.002_bib12","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.002_bib13","doi-asserted-by":"crossref","first-page":"22063","DOI":"10.1038\/s41598-021-01663-y","article-title":"A\u00a0meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)","volume":"11","author":"Ghosal","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.mcna.2024.03.002_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2021.609110","article-title":"Glucagon-like peptide-1 receptor agonists for non-alcoholic fatty liver disease in type 2 diabetes: a meta-analysis","volume":"12","author":"Wong","year":"2021","journal-title":"Front Endocrinol"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2024.03.002_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jcpt.13225","article-title":"Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes","volume":"45","author":"Trujillo","year":"2020","journal-title":"J\u00a0Clin Pharm Ther"},{"issue":"8","key":"10.1016\/j.mcna.2024.03.002_bib16","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s12630-023-02521-3","article-title":"Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report","volume":"70","author":"Gulak","year":"2023","journal-title":"Can J Anaesth"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.002_bib17","doi-asserted-by":"crossref","first-page":"E78","DOI":"10.1002\/ajh.25381","article-title":"Severe, prolonged thrombocytopenia in a patient sensitive to exenatide","volume":"94","author":"Vallatharasu","year":"2019","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.002_bib18","doi-asserted-by":"crossref","first-page":"e167952","DOI":"10.1172\/JCI167952","article-title":"Dual gut hormone receptor agonists for diabetes and obesity","volume":"133","author":"Bass","year":"2023","journal-title":"J\u00a0Clin Invest"},{"issue":"8","key":"10.1016\/j.mcna.2024.03.002_bib19","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis","volume":"65","author":"Karagiannis","year":"2022","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.002_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10402","key":"10.1016\/j.mcna.2024.03.002_bib21","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.002_bib22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.002_bib23","doi-asserted-by":"crossref","first-page":"bvad016","DOI":"10.1210\/jendso\/bvad016","article-title":"Adverse events related to tirzepatide","volume":"7","author":"Mishra","year":"2023","journal-title":"J\u00a0Endocr Soc"},{"key":"10.1016\/j.mcna.2024.03.002_bib24","doi-asserted-by":"crossref","first-page":"777861","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review","volume":"8","author":"Fonseca-Correa","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"10166","key":"10.1016\/j.mcna.2024.03.002_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"10365","key":"10.1016\/j.mcna.2024.03.002_bib26","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.002_bib27","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/dom.12825","article-title":"Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials","volume":"19","author":"Li","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.mcna.2024.03.002_bib28","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1185\/03007995.2012.697053","article-title":"Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor","volume":"28","author":"Nyirjesy","year":"2012","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"10.1016\/j.mcna.2024.03.002_bib29","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/M19-0085","article-title":"Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases","volume":"170","author":"Bersoff-Matcha","year":"2019","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.002_bib30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/00325481.2016.1153941","article-title":"Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials","volume":"128","author":"Johnsson","year":"2016","journal-title":"Postgrad Med"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.002_bib31","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.2337\/dc17-1551","article-title":"Empagliflozin and assessment of lower-limb amputations in the empa-reg outcome trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.002_bib32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1210\/jc.2015-1860","article-title":"Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.002_bib33","doi-asserted-by":"crossref","first-page":"e003666","DOI":"10.1136\/bmjdrc-2023-003666","article-title":"Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors","volume":"11","author":"Chow","year":"2023","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.002_bib34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7326\/M20-0289","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis : a multicenter cohort study","volume":"173","author":"Douros","year":"2020","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.mcna.2024.03.002_bib35","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/dom.14075","article-title":"Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials","volume":"22","author":"Liu","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.002_bib36","doi-asserted-by":"crossref","first-page":"506","DOI":"10.4158\/EP161447.LT","article-title":"Diabetic ketoacidosis in patients with type 2 diabetes recently commenced on SGLT-2 inhibitors: an ongoing concern","volume":"23","author":"Ahmed","year":"2017","journal-title":"Endocr Pract"},{"key":"10.1016\/j.mcna.2024.03.002_bib37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejim.2019.03.014","article-title":"Euglycemic diabetic ketoacidosis","volume":"63","author":"Barski","year":"2019","journal-title":"Eur J Intern Med"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.002_bib38","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1573399812666160421121307","article-title":"Euglycemic diabetic ketoacidosis: a review","volume":"13","author":"Modi","year":"2017","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.mcna.2024.03.002_bib39","first-page":"17","article-title":"Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma","volume":"2017","author":"Rawla","year":"2017","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.002_bib40","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4239\/wjd.v12.i5.514","article-title":"Euglycemic diabetic ketoacidosis: A missed diagnosis","volume":"12","author":"Nasa","year":"2021","journal-title":"World J Diabetes"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.002_bib41","first-page":"24","article-title":"Selecting the appropriate continuous glucose monitoring system - a practical approach","volume":"14","author":"Adolfsson","year":"2018","journal-title":"Eur Endocrinol"},{"key":"10.1016\/j.mcna.2024.03.002_bib42","first-page":"263","article-title":"Use of continuous glucose monitors to manage type 1 diabetes mellitus: progress, challenges, and recommendations","volume":"16","author":"Friedman","year":"2023","journal-title":"Pharmgenomics Pers Med"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2024.03.002_bib43","first-page":"S126","article-title":"7. diabetes technology: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mcna.2024.03.002_bib44","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa0805017","article-title":"Continuous glucose monitoring and intensive treatment of type 1 diabetes","volume":"359","author":"Tamborlane","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.002_bib45","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1210\/clinem\/dgab859","article-title":"Teamwork, targets, technology, and tight control in newly diagnosed type 1 diabetes: the pilot 4T study","volume":"107","author":"Prahalad","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"23","key":"10.1016\/j.mcna.2024.03.002_bib46","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1001\/jama.2020.6928","article-title":"Wireless innovation for seniors with diabetes mellitus (WISDM) study group. effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes: a randomized clinical trial","volume":"323","author":"Pratley","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.002_bib47","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1089\/dia.2021.0503","article-title":"Benefit of continuous glucose monitoring in reducing hypoglycemia is sustained through 12\u00a0months of use among older adults with type 1 diabetes","volume":"24","author":"Miller","year":"2022","journal-title":"Diabetes Technol Therapeut"},{"issue":"16","key":"10.1016\/j.mcna.2024.03.002_bib48","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa2205650","article-title":"Intermittently scanned continuous glucose monitoring for type 1 diabetes","volume":"387","author":"Leelarathna","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.mcna.2024.03.002_bib49","doi-asserted-by":"crossref","first-page":"e230085","DOI":"10.1530\/EC-23-0085","article-title":"Beyond A1C: exploring continuous glucose monitoring metrics in managing diabetes","volume":"12","author":"Friedman","year":"2023","journal-title":"Endocr Connect"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.002_bib50","doi-asserted-by":"crossref","first-page":"750","DOI":"10.2337\/dc21-2004","article-title":"Continuous glucose monitoring initiation within first year of type 1 diabetes diagnosis is associated with improved glycemic outcomes: 7-year follow-up study","volume":"45","author":"Champakanath","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.002_bib51","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2337\/dc11-1438","article-title":"Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes","volume":"35","author":"Vigersky","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mcna.2024.03.002_bib52","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/M16-2855","article-title":"Continuous glucose monitoring versus usual care in patients with Type 2 diabetes receiving multiple daily insulin injections: a randomized trial","volume":"167","author":"Beck","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2024.03.002_bib53","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13300-016-0223-6","article-title":"Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated Type 2 diabetes: a multicenter, open-label randomized controlled trial","volume":"8","author":"Haak","year":"2017","journal-title":"Diabetes Therapy: Research, Treatment and Education of Diabetes and Related Disorders"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.002_bib54","doi-asserted-by":"crossref","first-page":"bvab013","DOI":"10.1210\/jendso\/bvab013","article-title":"Flash CGM Is associated with reduced diabetes events and hospitalizations in insulin-treated type 2 diabetes","volume":"5","author":"Bergenstal","year":"2021","journal-title":"J\u00a0Endocr Soc"},{"key":"10.1016\/j.mcna.2024.03.002_bib55","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1001\/jama.2021.7444","article-title":"Effect of continuous glucose monitoring on glycemic control in patients with Type 2 diabetes treated with basal insulin: a randomized clinical trial","volume":"325","author":"Martens","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.002_bib56","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/dom.14949","article-title":"IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trial","volume":"25","author":"Aronson","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.mcna.2024.03.002_bib58","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.mcna.2024.03.002_bib59","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/00325481.2022.2110507","article-title":"Stepwise approach to continuous glucose monitoring interpretation for internists and family physicians","volume":"134","author":"Szmuilowicz","year":"2022","journal-title":"Postgrad Med"},{"issue":"11","key":"10.1016\/j.mcna.2024.03.002_bib60","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.2337\/dc18-1581","article-title":"Glucose management indicator (GMI): A new term for estimating A1C from continuous glucose monitoring","volume":"41","author":"Bergenstal","year":"2018","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.mcna.2024.03.002_bib61","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2337\/dc16-1769","article-title":"Toward defining the threshold between low and high glucose variability in diabetes","volume":"40","author":"Monnier","year":"2017","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.002_bib62","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.amjms.2018.09.010","article-title":"Glycemic variability: how to measure and its clinical implication for type 2 diabetes","volume":"356","author":"Umpierrez","year":"2018","journal-title":"Am J Med Sci"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.002_bib63","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/0145721720935123","article-title":"Technology integration: the role of the diabetes care and education specialist in practice","volume":"46","author":"Isaacs","year":"2020","journal-title":"Diabetes Educ"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.002_bib64","first-page":"47","article-title":"A\u00a0Comparison of insulin pen devices and disposable plastic syringes - simplicity, safety, convenience and cost differences","volume":"14","author":"Singh","year":"2018","journal-title":"Eur Endocrinol"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.002_bib65","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/dia.2018.0298","article-title":"Implementation of basal-bolus therapy in type 2 diabetes: a randomized controlled trial comparing bolus insulin delivery using an insulin patch with an insulin pen","volume":"21","author":"Bergenstal","year":"2019","journal-title":"Diabetes Technol Therapeut"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.002_bib66","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s12325-018-0703-3","article-title":"Clinical Benefits Over Time Associated with Use of V-Go Wearable Insulin Delivery Device in Adult Patients with Diabetes: A Retrospective Analysis","volume":"35","author":"Sutton","year":"2018","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.002_bib67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40801-019-00173-8","article-title":"Effectiveness of V-Go\u00ae for Patients with Type 2 Diabetes in a Real-World Setting: A Prospective Observational Study","volume":"7","author":"Grunberger","year":"2020","journal-title":"Drugs Real World Outcomes"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.002_bib68","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2337\/cd20-0094","article-title":"Evaluation of Clinical Outcomes With the V-Go Wearable Insulin Delivery Device in Patients With Type 2 Diabetes","volume":"39","author":"Meade","year":"2021","journal-title":"Clin Diabetes"},{"issue":"10","key":"10.1016\/j.mcna.2024.03.002_bib69","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1089\/dia.2023.0238","article-title":"Psychosocial Impact of the Insulin-Only iLet Bionic Pancreas for Adults, Youth, and Caregivers of Youth with Type 1 Diabetes","volume":"25","author":"Weissberg-Benchell","year":"2023","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.mcna.2024.03.002_bib70","doi-asserted-by":"crossref","first-page":"110730","DOI":"10.1016\/j.diabres.2023.110730","article-title":"Switching from treatment with sensor augmented pump to hybrid closed loop system in type 1 diabetes: Impact on glycemic control and neuropsychological tests in the real world","volume":"201","author":"Amig\u00f3","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.mcna.2024.03.002_bib71","doi-asserted-by":"crossref","first-page":"109998","DOI":"10.1016\/j.diabres.2022.109998","article-title":"How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the Omnipod\u00ae 5 System","volume":"190","author":"Polonsky","year":"2022","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712524000191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712524000191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T06:11:20Z","timestamp":1722319880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712524000191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":69,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0025712524000191"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2024.03.002","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Newer Outpatient Diabetes Therapies and Technologies","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2024.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}